Valuation dashboard for Aprea Therapeutics, Inc. (APRE) with P/E N/A, P/B 0.41, EV/EBITDA 0.72 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.73, APRE has negative trailing earnings (P/E not meaningful) and an ROE of -101.27%. Market capitalisation stands at $9M.
Balance sheet quality for APRE: current ratio of 5.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.41 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.14 |
| vs Current Price | +192.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | $9M | 0.41 | -101.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.73 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -101.27% |
| Return on Invested Capital | -100.49% |
| Return on Assets | -79.08% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APVO · BCDA · CELZ · GLTO · HCWB
Explore sector: Healthcare · Biotechnology
More sections of APRE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks